Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off, Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage.

IF 0.5 Q4 OPHTHALMOLOGY

Journal of VitreoRetinal Diseases Pub Date : 2024-11-12 DOI:10.1177/24741264241297684

Melissa Yuan, Sandra Hoyek, Leo A Kim, Celine Chaaya, Nimesh Patel

{"title":"Antivascular Endothelial Growth Factor Injections for the Chronic Treatment of Macula-off, Fovea-on Diabetic Tractional Retinal Detachment With Vitreous Hemorrhage.","authors":"Melissa Yuan, Sandra Hoyek, Leo A Kim, Celine Chaaya, Nimesh Patel","doi":"10.1177/24741264241297684","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the use of antivascular endothelial growth factor (anti-VEGF) as treatment for tractional retinal detachments (TRDs) involving the macula. Methods: A case report was evaluated. Results: A 40-year-old man with a medical history notable for congenital heart disease and proliferative diabetic retinopathy presented with decreased vision. Surgery was not feasible for medical reasons, and panretinal photocoagulation was limited by retinal traction and hemorrhage. Despite initial progression of bilateral macula-off, foveal-on TRDs, the patient received intravitreal (IVT) bevacizumab regularly every 8 to 12 weeks. After initial improvement, both eyes remained anatomically stable with attached foveas over more than 1.5 years of follow-up. Conclusions: In cases in which surgery is not possible, macula-involving TRDs with neovascularization can be managed successfully with repeated IVT anti-VEGF injection monotherapy.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241297684"},"PeriodicalIF":0.5000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558646/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264241297684","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the use of antivascular endothelial growth factor (anti-VEGF) as treatment for tractional retinal detachments (TRDs) involving the macula. Methods: A case report was evaluated. Results: A 40-year-old man with a medical history notable for congenital heart disease and proliferative diabetic retinopathy presented with decreased vision. Surgery was not feasible for medical reasons, and panretinal photocoagulation was limited by retinal traction and hemorrhage. Despite initial progression of bilateral macula-off, foveal-on TRDs, the patient received intravitreal (IVT) bevacizumab regularly every 8 to 12 weeks. After initial improvement, both eyes remained anatomically stable with attached foveas over more than 1.5 years of follow-up. Conclusions: In cases in which surgery is not possible, macula-involving TRDs with neovascularization can be managed successfully with repeated IVT anti-VEGF injection monotherapy.

查看原文本刊更多论文

抗血管内皮生长因子注射液用于慢性治疗黄斑脱离、眼窝脱离伴玻璃体出血的糖尿病牵拉性视网膜脱离。

目的：评估使用抗血管内皮生长因子（anti-VEGF）治疗涉及黄斑的牵引性视网膜脱离（TRD）的效果。方法：评估一份病例报告：对一份病例报告进行评估。结果：一名 40 岁男子因先天性心脏病和增殖性糖尿病视网膜病变导致视力下降。由于医疗原因，手术并不可行，而全视网膜光凝又受到视网膜牵引和出血的限制。尽管最初双侧黄斑-关闭、眼窝-开启的TRD有所进展，但患者仍接受了每8至12周定期进行的玻璃体内（IVT）贝伐单抗治疗。最初病情有所好转后，在超过1.5年的随访中，双眼的视网膜仍保持解剖学上的稳定。结论是在无法进行手术的情况下，通过重复IVT抗血管内皮生长因子注射单药治疗，可以成功控制伴有新生血管的黄斑受累TRD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of VitreoRetinal Diseases

CiteScore

1.20

自引率

16.70%

发文量